Trial Profile
Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Gilteritinib (Primary) ; Idarubicin (Primary) ; Midostaurin (Primary) ; Venetoclax (Primary)
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 04 May 2023 Planned End Date changed from 31 May 2024 to 31 May 2026.
- 04 May 2023 Planned primary completion date changed from 31 May 2023 to 31 May 2025.
- 13 Dec 2022 updated results and longer term follow-up (n=67), presented at the 64th American Society of Hematology Annual Meeting and Exposition